House passes AHA-supported bills to promote generic drug competition
The House of Representative today passed two AHA-supported bills to promote generic and biosimilar competition in the prescription drug market. The Orange Book Transparency Act (H.R. 1503) and Purple Book Continuity Act (H.R. 1520) would increase the accuracy and transparency of the two databases that guide development decisions for generic and biosimilar manufacturers.
Related News Articles
Headline
The Trump administration announced Aug. 31 agreements with nine additional pharmaceutical manufacturers aimed at lowering prescription drug prices through a…
Headline
The AHA’s American Organization for Nursing Leadership will host a webinar Sept. 2 at noon ET for nursing leaders on two care models: integrated hospital-at-…
Headline
The AHA Aug. 17 provided comments to the Centers for Medicare & Medicaid Services on its proposed rule to codify in regulation the Medicare Drug Price…
Headline
The 5th U.S. Circuit Court of Appeals Aug. 11 ruled to vacate certain regulations implementing how the No Surprises Act qualifying payment amount is calculated…
Headline
Update: The Senate passed the continuing resolution Aug. 8 by a vote of 90-6 and one present vote. The Senate is expected to vote this week on its own…
Headline
The AHA July 27 expressed support for the National Nursing Workforce Center Act of 2025 (S. 1482), legislation that would establish state-based nursing…